Bi-function ligand targeting dendritic cell tumor vaccine and preparation method thereof

Abstract

The invention relates to a bi-function ligand targeting dendritic cell tumor vaccine and a preparation method thereof. The method comprises the following steps: S1)preparing mannose modified nanoliposomes; S2)connecting CpG-ODN to the nanoliposomes to obtain the bi-function ligand modified nanoliposomes; S3)extracting tumour antigen peptide from tumor cells by a repeated thawing-freezing method; and S4) coating tumour antigen peptide by the ligand modified nanoliposomes by a freeze-drying-rehydration method. According to the invention, the bi-function ligand modified nanoliposomes can be taken as a carrier, mannose molecules on surface of liposome is specifically targeted to dendritic cells, CpG-ODN is combined to a Toll acceptor 9 in the dendritic cells for promoting the maturation of dendritic cells, matured dendritic cells enables high efficiency presentation of tumour antigen peptide released from inner part of nanoliposomes, T lymphocyte can be activated, and specific antineoplastic effect is generated.

Description

technical field [0001] The invention belongs to the medical basic application field of biological materials, and more specifically relates to a bifunctional ligand-targeted dendritic cell (DC) tumor vaccine and a preparation method thereof. Background technique [0002] Tumor is one of the major diseases that seriously endanger human health. Although traditional methods such as surgical resection, local or systemic chemotherapy and radiotherapy have made some progress, new anti-tumor methods still need to be explored. [0003] Dendritic cells (DCs) are the professional antigen-presenting cells (APCs) with the strongest ability in vivo known to date, and they are also the only APCs that can induce primary immune responses and activate unsensitized T cells. As the initiator of antigen-specific immune response, DC plays a central role in the body's anti-tumor immune response. The ability of DCs to induce immune effector cells in tumor infiltrating tissues is low, because duri...

AI Technical Summary

Problems solved by technology

[0005] The technical problem to be solved by the present invention is to provide a DC-targeted tumor vaccine with a dual-functional ligand and a preparation method thereof for the problems of weak targeting and low antigenic stimulation of tumor antigen peptide vaccines in existing tumor active immunotherapy

Images